Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) ...
Adjusted EBITDA(1) is positive for each of the last 3 years; Adjusted Working Capital(2) is approximately positive $2 million— Loan Interest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback